Larimar Therapeutics names John Harlow president and COO

PUBT · 1d ago
Larimar Therapeutics names John Harlow president and COO
  • Larimar Therapeutics named John Harlow president and chief operating officer, effective Sept. 29, 2026, reporting to CEO Carole Ben-Maimon.
  • Harlow most recently served as chief commercial officer at Esperion Therapeutics, leading commercial operations, business development, global alliance management.
  • He previously held chief commercial officer roles at Melinta Therapeutics and executive positions at Baudax Bio, Recro Pharma, Endo Pharmaceuticals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291605PRIMZONEFULLFEED9834362) on September 29, 2026, and is solely responsible for the information contained therein.